A synthetic analogue of phosphatidylinositol mannoside is an efficient adjuvant

Immunopharmacology and Immunotoxicology

Volumn 31, Issue 4, 2009, Pages 577-582

  Denis, Michel ^a   Ainge, Gary D ^b,c   Larsen, David S ^c   Severn, Wayne B ^b   Painter, Gavin F ^b  

^a AGRESEARCH GRASSLANDS   (New Zealand)

^b CALLAGHAN INNOVATION   (New Zealand)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Adjuvant; Hepatitis C; Interferon; Interleukin 12; Phosphatidylinositol mannoside

Indexed keywords

2,6 (DI O ALPHA DEXTRO MANNOPYRANOSYL) 1 O (1 O HEXADECANOYL 2 O HEXADECYL SN GLYCERO 3 PHOSPHORYL) DEXTRO MYOINOSITOL; ALUMINUM POTASSIUM SULFATE; BIOLOGICAL MARKER; GAMMA INTERFERON; GLYCEROPHOSPHOLIPID; HEPATITIS C ANTIGEN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 12P40; PHOSPHORYL LIPID A; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS C; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION; WEIGHT REDUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BIOLOGICAL MARKERS; CELLS, CULTURED; EPITOPES, T-LYMPHOCYTE; FEMALE; IMMUNITY, CELLULAR; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-12 SUBUNIT P40; MICE; MICE, INBRED C57BL; PHOSPHATIDYLINOSITOLS; RANDOM ALLOCATION; SPLEEN; TH1 CELLS;

ANIMALIA; HEPATITIS C VIRUS; MUS;

EID: 70449097997     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923970902824862     Document Type: Article

References (30)

1. Rastogi, N., David H.L. Mechanisms of pathogenicity in mycobacteria. Biochimie. 1988,70(8),1101-1120.
2. Cox, J, Coulter, A. Prospects for the development of new vaccine adjuvants. BioDrugs. 1999,12(6),439-453.
3. Briken, V, Porcelli, S.A., Besra, G.S., Kremer, L. Mycobacterial lipoarabinomannan and related lipoglycans: From biogenesis to modulation of the immune response. Mol Microbiol. 2004,53(2),391-403.
4. Azuma, I, Seya, T. Development of immunoadjuvants for immunotherapy of cancer. Int. Immunopharmacol. 2001,1(1),1249-1259.
5. Pichichero, M.E. Improving vaccine delivery using novel adjuvant systems. Hum VaccineS. 2008,4(4),262-270.
6. Chedid, L, Audibert, F. Chemically defined bacterial products with immunopotentiating activity. J Infect Dis. 1977,136,S246-251.
7. Petrovsky, N. Freeing vaccine adjuvants from dangerous immunological dogma. Expert Rev Vaccines. 2008,7 (1),7-10.
8. Khoo, K.H., Dell A., Morris, H.R., et al. Structural definition of acylated phosphatidylinositol mannosides from Mycobacterium tuberculosis: Definition of a common anchor for lipomannan and lipoarabinomannan. Glycobiology. 1995,5(2),117-127.
9. Gilleron, M., Ronet, C., Mempel, M., et al. Acylation state of the phosphatidylinositol mannosides from Mycobacterium bovis bacillus Calmette Guérin and ability to induce granuloma and recruit natural killer T cells. J Biol Chem. 2001,276(37),34896-34904
10. Gilleron, M, Quesniaux, V.F., Puzo, G. Acylation state of the phosphatidylinositol hexamannosides from Mycobacterium bovis bacillus Calmette Guerin and mycobacterium tuberculosis H37Rv and its implication in Toll-like receptor response. J Biol Chem. 2003,278(32),29880-29889.
11. Ainge, G.D., Parlane N.A., Denis, M, et al. Phosphatidylinositol mannoside ether analogues: Syntheses and interleukin-12- inducing properties. J Org Chem. 2007,7(14),5291-5296.
12. Parlane, N.A., Denis, M, Severn, W.B., et al. Phosphatidylinositol mannosides are efficient mucosal adjuvants. Immunol Invest. 2008,37(2),129-142.
13. Ainge, G. D., Parlane, N. A., Denis, M., et al. Phosphatidylinositol mannosides: Synthesis and adjuvant properties of phosphatidylinositol di- and tetramannosides. Bioorg Med Chem. 2006,14(22),7615-7624.
14. Fitzmaurice, K, Klenerman, P. Cellular immunity and acute hepatitis C infection. Curr. Pharm. Des. 2008,14(17),1666-1677.
15. Strickland, G.T., El-Kamary, S.S., Klenerman, P., Nicosia, A. Hepatitis C vaccine: Supply and demand. Lancet Infect Dis. 2008,8 (6),379-386.
16. Wedlock, D.N., Denis, M, Painter, G.F., et al. Enhanced protection against bovine tuberculosis after coadministration of Mycobacterium bovis BCG with a Mycobacterial protein vaccine- adjuvant combination but not after coadministration of adjuvant alone. Clin Vaccine Immunol. 2008,15 (5),765-772.
17. Sprott, G.D., Dicaire, C.J., Gurnani, K., et al. Activation of dendritic cells by liposomes prepared from phosphatidylinositol mannosides from Mycobacterium bovis bacillus Calmette-Guerin and adjuvant activity in vivo. Infect Immun. 2004,72(9),5235-5246.
18. Mehta, P.K., Khuller, G.K. Protective immunity to experimental tuberculosis by mannophosphoinositides of mycobacteria. Med. Microbiol. Immunol. 1988,177(21),265-284.
19. Sayers, I, Severn, W., Scanga, C.B., et al. Suppression of allergic airway disease using mycobacterial lipoglycans. J Allergy Clin Immunol. 2004,114(2),302-309.
20. Fischer, K, Scotet, E, Niemeyer, M, et al. Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells. Proc Natl Acad Sci USA. 2004,101(29),10685-10690.
21. Jones, B.W., Heldwein, K.A., Means, T.K., et al. Differential roles of Toll-like receptors in the elicitation of proinflammatory responses by macrophages. Ann Rheum Dis. 2001,60Suppl,6-12.
22. Jones, B.W., Means, T.K., Heldwein, K.A., et al. Different Tolllike receptor agonists induce distinct macrophage responses. J Leukoc Biol. 2001,69(6),1036-1044.
23. Rojas, R.E., Thomas, J.J., Gehring, A.J., et al. Phosphatidylinositol mannoside from Mycobacterium tuberculosis binds alpha5beta1 integrin (VLA-5) on CD4+ T cells and induces adhesion to fibronectin. J Immunol. 2006,177(5),2959-2968.
24. Torrelles, J.B., Azad, A.K., Schlesinger, L.S. Fine discrimination in the recognition of individual species of phosphatidylmyo- inositol mannosides from Mycobacterium tuberculosis by C-type lectin pattern recognition receptors. J Immunol. 2006,177(3),1805-1816.
25. Persing, D.H., Coler, R.N., Lacy, M.J., et al. Taking toll: Lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol. 2002,10(10 Suppl),S32-S37.
26. Marshall, J.D., Abtahi, S., Eiden, J.J., et al. Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy. J Allergy Clin Immunol. 2001,108(2),191-197.
27. Hegazy, D., Thurairajah, P., Metzner, M., et al. Interleukin 12B gene polymorphism and apparent resistance to hepatitis C virus infection. Clin Exp Immunol. 2008,152(3) ,538-541.
28. Waggoner, S.N., Hall, C.H., Hahn, Y.S. HCV core protein interaction with gC1q receptor inhibits Th1 differentiation of CD4+ T cells via suppression of dendritic cell IL-12 production. J Leukoc Biol. 2007,82(6),1407-1419
29. Pachiadakis, I, Pollara G, Chain, B.M., Naoumov, N.V. Is hepatitis C virus infection of dendritic cells a mechanism facilitating viral persistence? Lancet Infect Dis. 2005,5(5),296-304.
30. Jin, B., Wang, R.Y., Qiu, Q., et al. Induction of potent cellular immune response in mice by hepatitis C virus NS3 protein with double-stranded RNA. Immunology. 2007,122(1),15-27.